May explain some observations of systemically administered peptides producing retinal effects despite theoretical barrier restrictions
By reducing appetite, stabilizing blood sugar, and supporting healthy eating habits, it helps patients achieve meaningful, long-term results
Who Is a Good Candidate for GLP-1s
with FDA-approved products containing semaglutide, identified under the names Wegovy, Ozempic, and Rybelsus: Semaglutide acts as a satiety hormone, so it makes you feel full
Several case reports indicate that the concurrent use of GLP-1RAs and dipeptidyl peptidase-IV inhibitors (DPP-4Is) might elevate the risk of developing specific cancers, such as breast, thyroid, and pancreatic cancers [124]